Dendrobium officinale flower extract PGG100 and application thereof in skin care

Abstract

The invention provides a Dendrobium officinale Kimura amp (Migo) flower extract PGG100 and an application of the Dendrobium officinale Kimura amp (Migo) flower extract PGG100 in the technical field of cosmetics and medicines. The PGG100 (100 [mu] g / mL) provided by the invention can significantly improve the expression quantity of the human dermal fibroblast elastin gene Elastin under UVA radiation, and does not show obvious cytotoxicity to human fibroblasts in a concentration range of 800 [mu] g / mL. The PGG100 can be used for preparing cosmetics or medicines for resisting skin aging caused by UVA, repairing skin injury, reducing scar formation, repairing wounds and promoting elastin gene expression and synthesis.

Description

Technical Field

[0001] This invention belongs to the field of cosmetics and pharmaceutical technology, specifically relating to the field of plant-based cosmetics and medicinal plants, and more specifically, to Dendrobium officinale flower extract PGG100, compositions thereof, and its application in the preparation of cosmetics and pharmaceuticals. It is used to prepare cosmetics or pharmaceuticals that combat UVA-induced skin aging, repair skin damage, reduce scar formation, promote wound healing, and enhance elastin gene expression and synthesis. Background Technology

[0002] The skin is the body's main protective barrier, composed of the epidermis, dermis, and subcutaneous tissue. The dermis is mainly composed of fibroblasts and the extracellular matrix (ECM) they produce, with elastin accounting for approximately 0.6%–7.9% of the ECM [Gardeazabal L., Izeta A. Elastin and collagen fibres in cutaneous wound healing. Experimental Dermatology, 2024, 33 (3), e15052]. In ultraviolet (UV) radiation, long-wave UVA (320–400 nm) can penetrate deep into the dermis, triggering a series of pathological events, including excessive generation of reactive oxygen species (ROS), activation of matrix metalloproteinases (MMPs), and degradation of ECM components such as collagen and elastin. These processes ultimately lead to decreased skin elasticity, wrinkle formation, and impaired barrier function, necessitating effective preventative strategies [Fu B., WanY., Ma X., Chang Z., Yang X., Liu X., Wu H., Cheng S., Du M. Salmon leathercollagen peptide alleviates UVA-induced photoaging via Nrf2 / Keap1 pathway by enhancing antioxidant defense and preserving skin elasticity. FoodBioscience, 2025, 72, 107494]. Elastin is abundant in normal skin and common scars, but rarely found in hypertrophic scars or keloids [Labadie JG, Dasgeb B., Phillips TJ, Arndt K. A., What Are Scars? In Procedures in Cosmetic Dermatology: Scar Management (Second Edition), Labadie, JG; Alam, M.; Dover, JS, Eds. Elsevier:2025; pp 1-10]. The soft tissue of scars treated with pressure therapy showed significant improvement in flexibility, and the transcriptional level and expression of elastin were increased [Zhang Yixin, Chai Jun. Mechanism and clinical application of pressure therapy for scars. Chinese Journal of Burns and Wound Repair, 2025, 41 (4), 316-324].Therefore, promoting the expression of elastin genes and the synthesis of elastin is beneficial for combating skin aging caused by UVA, for repairing skin damage, and for reducing scar formation. Summary of the Invention

[0003] This invention is based on the significant activity and function of Yunnan Paris saponin G (PFV85) in promoting elastin gene expression and elastin synthesis, possessing the ability to combat UVA-induced skin aging, repair skin damage, reduce scar formation, and repair wounds. The aim is to provide a novel Dendrobium officinale flower extract PGG100, pharmaceutical compositions or cosmetics containing it, and its application in the preparation of cosmetics and pharmaceuticals. Specifically, it provides its application in the preparation of anti-skin aging drugs, drugs for reducing scar formation, and drugs for repairing skin damage, repairing wounds, and promoting elastin gene expression and synthesis. It also provides its application in the preparation of cosmetics for combating UVA-induced skin aging, cosmetics for repairing skin damage, and cosmetics for reducing scar formation, repairing wounds, and promoting elastin gene expression and synthesis.

[0004] To achieve the above-mentioned objectives of the present invention, the present invention provides the following technical solution:

[0005] Dendrobium officinale flower extract PGG100 is prepared by the following method:

[0006] Dried Dendrobium officinale flowers were extracted three times with 90% ethanol at 70 °C for 3 h each time. The extracts were combined and concentrated using a rotary evaporator at 60 °C to obtain a crude extract. Distilled water was added to the crude extract to form a suspension, and an equal volume of petroleum ether was added for extraction five times. The organic phase was concentrated under reduced pressure using a rotary evaporator at 60 °C to obtain the petroleum ether extract. After petroleum ether extraction, the remaining aqueous phase was extracted five times with an equal volume of ethyl acetate. The organic phase was concentrated under reduced pressure using a rotary evaporator at 60 °C to obtain the ethyl acetate extract. After ethyl acetate extraction, an equal volume of n-butanol was extracted five times. The organic phase was concentrated under reduced pressure using a rotary evaporator at 60 °C to obtain the n-butanol extract PGG100.

[0007] A method for preparing Dendrobium officinale flower extract PGG100 includes the following steps: Dried Dendrobium officinale flowers are extracted three times with 90% ethanol at 70 °C for 3 h each time. The extracts are combined and concentrated using a rotary evaporator at 60 °C to obtain a crude extract. Distilled water is added to the crude extract to form a suspension, and an equal volume of petroleum ether is added for extraction five times. The organic phase is concentrated under reduced pressure using a rotary evaporator at 60 °C to obtain the petroleum ether extract. After petroleum ether extraction, the remaining aqueous phase is extracted five times with an equal volume of ethyl acetate. The organic phase is concentrated under reduced pressure using a rotary evaporator at 60 °C to obtain the ethyl acetate extract. After ethyl acetate extraction, an equal volume of n-butanol is extracted five times. The organic phase is concentrated under reduced pressure using a rotary evaporator at 60 °C to obtain the n-butanol extract PGG100.

[0008] The application of the Dendrobium officinale flower extract PGG100 in the preparation of drugs for anti-UVA-induced skin aging, repair of skin damage, and reduction of scar formation.

[0009] The pharmaceutical composition comprises the aforementioned Dendrobium officinale flower extract PGG100 and a pharmaceutically acceptable carrier.

[0010] The pharmaceutical composition is used in the preparation of drugs for anti-UVA-induced skin aging, repair of skin damage, and reduction of scar formation.

[0011] The method for preparing the pharmaceutical composition includes the following steps: first, obtaining Dendrobium officinale flower extract PGG100 by the PGG100 preparation method, and then adding a pharmaceutically acceptable carrier.

[0012] The cosmetic uses the aforementioned Dendrobium officinale flower extract PGG100 as the active ingredient, along with conventional cosmetic excipients.

[0013] The application of the Dendrobium officinale flower extract PGG100 in the preparation of cosmetics for anti-UVA-induced skin aging, repair of skin damage, and reduction of scar formation.

[0014] The method for preparing the cosmetic includes the following steps: first, obtaining Dendrobium officinale flower extract PGG100 by the PGG100 preparation method, and then adding commonly used cosmetic excipients.

[0015] The application of the Dendrobium officinale flower extract PGG100 in the preparation of drugs or cosmetics that promote elastin gene expression and synthesis.

[0016] The application of the Dendrobium officinale flower extract PGG100 in the preparation of wound repair drugs or cosmetics.

[0017] In this invention, when the extract PGG100 or its composition is used to prepare a drug, the content of the extract or its composition in the drug is preferably 0.1% to 99%; in the drug composition, the content of any one or any combination of the active ingredient extracts is preferably 0.5% to 90%. The drug composition of this invention is preferably used in the form of a dose per unit body weight. In this invention, the prepared drug is preferably administered orally or topically. The drug preparations include topical ointments, tablets, capsules, nasal sprays, pills, drops, etc., including but not limited to the above-mentioned preparations.

[0018] In this invention, when the extract PGG100 is used to prepare cosmetics, the formulation of the cosmetics is not limited and can be prepared using conventional cosmetic preparation methods.

[0019] Compared with the prior art, the present invention has the following advantages:

[0020] 1. The Dendrobium officinale Kimura & Migo flower extract PGG100 provided by this invention can significantly promote the expression of elastin gene in human dermal fibroblasts under UVA radiation.

[0021] 2. The Dendrobium officinale Kimura & Migo flower extract PGG100 provided by this invention has no toxicity to human dermal fibroblasts in the concentration range of 800 μg / mL.

[0022] 3. PGG100, an extract of Dendrobium officinale (Kimura & Migo) flowers, exhibits significant activity in promoting elastin gene expression and elastin synthesis, and can be used to prepare drugs or cosmetics that promote elastin gene expression and synthesis. It also possesses pharmacological effects and functions in combating UVA-induced skin aging, repairing skin damage, reducing scar formation, and repairing wounds, and can be used to prepare drugs or cosmetics with similar functions and effects. Attached Figure Description

[0023] Figure 1 The Dendrobium officinale Kimura & Migo flower extract PGG100 provided by this invention did not show significant cytotoxicity against human dermal fibroblasts in the concentration range of 800 μg / mL. Detailed Implementation

[0024] The following description, in conjunction with the accompanying drawings, uses embodiments of the present invention to further illustrate the substantive content of the invention, but does not limit the invention thereto.

[0025] Example 1

[0026] Preparation of PGG100, an extract from the flowers of Dendrobium officinale Kimura & Migo:

[0027] 4.5 kg of dried Dendrobium officinale flowers were extracted three times with 50 L of 90% ethanol at 70 °C for 3 h each time. The extracts were combined and concentrated using a rotary evaporator at 60 °C to obtain 1.5 kg of crude extract. 1.5 L of distilled water was added to the crude extract to form a suspension, which was then extracted five times with an equal volume of petroleum ether. The organic phase was concentrated under reduced pressure using a rotary evaporator at 60 °C to obtain the petroleum ether extract (253.1 g). After petroleum ether extraction, the remaining aqueous phase was extracted five times with an equal volume of ethyl acetate. The organic phase was concentrated under reduced pressure using a rotary evaporator at 60 °C to obtain the ethyl acetate extract (69.5 g). After ethyl acetate extraction, the organic phase was extracted five times with an equal volume of n-butanol. The organic phase was concentrated under reduced pressure using a rotary evaporator at 60 °C to obtain the n-butanol extract (163.9 g), which is PGG100.

[0028] Example 2

[0029] Activity assay of PGG100, an extract of Dendrobium officinale flowers:

[0030] 1. Cell

[0031] The cells used in this test were human dermal fibroblasts, batch number: Fb230131, provided by Guangdong Boxi Shaanxi Branch.

[0032] 2. Main reagents

[0033] DMEM culture medium (Gibco), fetal bovine serum (Lanzhou Rongye), PBS (Solepro), MTT (Sigma), DMSO (Sigma), AG RNAex Pro Reagent (Aikerui Biotechnology), reverse transcription kit (Aikerui Biotechnology), fluorescent dye (Aikerui Biotechnology), TGF-β1 (Peprotech).

[0034] 3. Main Equipment

[0035] CO2 incubator (Thermo, 150I), ultra-clean workbench (Sujing Antai, SW-CJ-2F), microplate reader (BioTek, Epoch), UVA irradiator (Philips), inverted microscope (Olympus, CKX53), and real-time PCR instrument (Roche, Lightcycler 480 II).

[0036] 4. Cytotoxicity assay based on human dermal fibroblasts

[0037] 4.1 Cell viability testing methods

[0038] 1) Cell seeding: After cell resuscitation, when the cell plating rate reaches about 50%~60%, seed the cells into 96-well plates and incubate overnight in a CO2 incubator (37 °C, 5% CO2).

[0039] 2) Experimental Groups: The experiment included a zeroing group, a solvent control group, a positive control group, and a sample group. In the sample group, each sample had 8 concentration gradients, and each concentration gradient had 3 replicate wells.

[0040] 3) Solution preparation: Prepare working solutions of the PGG100 sample to be tested with concentrations of 6.25 μg / mL, 12.5 μg / mL, 25 μg / mL, 50 μg / mL, 100 μg / mL, 200 μg / mL, 400 μg / mL and 800 μg / mL.

[0041] 4) Drug administration: Drug administration was performed when the cell seeding rate in the 96-well plate reached 50%–60%. For the solvent control group, 200 μL of culture medium was added to each well; for the positive control group, 200 μL of culture medium containing 10% DMSO was added to each well; for the sample group, 200 μL of culture medium containing the corresponding concentration of the sample was added to each well; for the zeroing group, no cells were seeded, only 200 μL of cell culture medium was added. After drug administration, the 96-well plate was placed in a CO2 incubator (37 ℃, 5% CO2) and incubated for 24 h.

[0042] 5) Detection: After culturing cells for 24 h, discard the supernatant, add MTT working solution (0.5 mg / mL), and incubate at 37 ℃ in the dark for 4 h. After incubation, discard the supernatant, add 150 μL DMSO to each well, and read the OD value at 490 nm.

[0043] 6) Calculation of relative cell viability: According to the formula, relative cell viability (%) = [(sample well OD − zeroing well OD) / (solvent control well OD − zeroing well OD)] × 100%.

[0044] 4.2 Cell morphology testing methods

[0045] 1) Cell seeding: After cell resuscitation, when the cell seeding rate reaches about 50%~60%, seed the cells into 24-well plates and incubate overnight in a CO2 incubator (37 °C, 5% CO2).

[0046] 2) Experimental Groups: The experiment included a solvent control group and a sample group. Within the sample group, five concentration gradients were set up (50 μg / mL, 100 μg / mL, 200 μg / mL, 400 μg / mL, and 800 μg / mL).

[0047] 3) Drug administration: Drug administration was performed when the cell deposition rate in the 24-well plate reached 50%–60%. 1 mL of culture medium was added to each well of the solvent control group; 1 mL of culture medium containing the corresponding concentration of the test sample was added to each well of the sample group. After drug administration, the 24-well plate was placed in a CO2 incubator (37 °C, 5% CO2) and incubated for 24 h.

[0048] 4) Take photos: After incubation, discard the supernatant and take photos under an inverted microscope.

[0049] 4.3 Test Results

[0050] Based on MTT (Table 1) and morphological results ( Figure 1 Based on human fibroblasts, PGG100 did not show significant cytotoxicity at concentrations in the range of 800 μg / mL.

[0051] Table 1. MTT assay results of PGG100 on human dermal fibroblasts

[0052] sample concentration Cell viability (%) PGG100 6.25 μg / mL 97.14 ± 0.55 PGG100 12.5 μg / mL 96.82 ± 0.68 PGG100 25 μg / mL 94.50 ± 0.89 PGG100 50 μg / mL 93.89 ± 1.53 PGG100 100 μg / mL 93.90 ± 0.49 PGG100 200 μg / mL 92.23 ± 3.50 PGG100 400 μg / mL 91.94 ± 3.26 PGG100 800 μg / mL 91.11 ± 0.89 DMSO (positive control) 10% 6.72 ± 2.06 negative control - 100.00 ± 0.67

[0053] 5. Gene expression level assay based on fibroblasts

[0054] 5.1 Test Method

[0055] 1) Cell seeding: After cell resuscitation, when the cell plating rate reaches about 60%, seed the cells into 6-well plates and incubate overnight in a CO2 incubator (37 °C, 5% CO2).

[0056] 2) Solution preparation: Prepare working solutions for the test substances according to the test groups.

[0057] 3) Drug administration: According to the test groups, when the cell deposition rate in the 6-well plate reached 30%~50%, drug administration was performed in groups, with 3 replicates per group. 2 mL of culture medium was added to each well of the blank control group and negative control group, 2 mL of culture medium containing the corresponding concentration of TGF-β1 was added to each well of the positive control group, and 2 mL of culture medium containing the corresponding concentration of the test sample was added to each well of the sample group. After drug administration, the 6-well plate was incubated in a CO2 incubator (37 °C, 5% CO2) for 24 h.

[0058] 4) UVA irradiation: According to the test grouping, all groups except the blank control group were subjected to UVA irradiation with an irradiation dose of 30 J / cm². 2 After irradiation, the samples were placed in an incubator (37 °C, 5% CO2) and cultured for another 24 h.

[0059] 5) Cell collection: After incubation, aspirate the old solution, wash twice with PBS, add 1 mL of AG RNAex ProReagent to each well, lyse the cells by pipetting, and collect the sample.

[0060] 6) Gene expression detection: RNA was extracted, reverse transcribed into cDNA, and then detected by real-time quantitative PCR using 2... -△△CT The method is used to calculate the results.

[0061] 7) Calculation of upward adjustment rate:

[0062] Upregulation rate (%) = [(Sample group − Blank control group) / Blank control group] × 100%

[0063] 8) Statistical Analysis of Results: GraphPad Prism Program software was used for plotting, and the results are expressed as Mean ± SD. t-tests were used for comparisons between groups. All statistical analyses were two-tailed. P < 0.05 was considered statistically significant, and P < 0.01 was considered highly statistically significant.

[0064] 5.2 Results of Elastin Gene Expression Test

[0065] The test results are shown in Table 2. Compared with the blank control (BC) group, the expression level of Elastin gene in the negative control (NC) group was significantly downregulated, indicating that the stimulation conditions of this test were effective. Compared with the NC group, the expression level of Elastin gene in the positive control (PC) group was significantly upregulated, indicating that the positive control of this test was effective. Compared with the NC group, the expression level of Elastin gene in sample PGG100 (100 μg / mL) was significantly upregulated, with an upregulation rate of 36.11%.

[0066] Table 2. Results of Elastin gene detection

[0067] Group Mean expression level SD P-value Upward adjustment rate (vs NC) BC 1.00 0.12 - - NC 0.72 0.06 <![CDATA[0.019 # ]]> - PC 2.95 0.28 0.000** 309.72% PGG100 (100 μg / mL) 0.98 0.11 0.023* 36.11%

[0068] Note: Use 2 -△△CT When calculating the results using the method and performing statistical analysis using the t-test, the significance level compared to the BC group was [missing information]. # This means that P < 0.05 indicates that... # P < 0.01 indicates that ## Compared with the NC group, significance is indicated by *, P < 0.05 is indicated by *, and P < 0.01 is indicated by **.

[0069] Example 3:

[0070] Cream formula containing Dendrobium officinale flower extract PGG100 (W%):

[0071] Dendrobium officinale flower extract PGG100 0.03

[0072] Stearic acid 8.0

[0073] C16 alcohol 2.0

[0074] Self-emulsifying monoglyceride 2.0

[0075] Hydrogenated lanolin 2.0

[0076] Liquid paraffin 12.0

[0077] Glycerin 7.0

[0078] Emulsifier 1.5

[0079] Preservative 0.2

[0080] Fragrance 0.2

[0081] Add deionized water to 100

[0082] The cosmetic product of the above-described formula of the present invention is prepared using conventional methods for manufacturing cosmetics.

[0083] Example 4:

[0084] Emulsion formulation (W%) containing Dendrobium officinale flower extract PGG100:

[0085] Dendrobium officinale flower extract PGG100 0.03

[0086] Stearic acid 1.4

[0087] Cetyl alcohol 0.1

[0088] 2-Ethyl alcohol cetyl stearate 1.8

[0089] Isopropyl myristate 0.2

[0090] 2-Hexyl-1-decyl alcohol 1.0

[0091] Liquid paraffin 7.5

[0092] Glycerin 3.0

[0093] Propylene glycol 8.0

[0094] Triethanolamine 1.0

[0095] Carboxyvinyl polymer 0.35

[0096] Arlacel 165 2.0

[0097] Preservative 0.2

[0098] Fragrance 0.2

[0099] Add deionized water to 100

[0100] The cosmetic product of the above-described formula of the present invention is prepared using conventional methods for manufacturing cosmetics.

[0101] Example 5

[0102] Facial cleanser containing Dendrobium officinale flower extract PGG100.

[0103] 1. Materials

[0104] The Dendrobium officinale flower extract PGG100 obtained by the same method as in Example 1 uses cosmetic-grade or food-grade raw materials.

[0105] 2. Formula

[0106] Dendrobium officinale flower extract PGG100 0.5 g, glycerin 3.0 g, butylene glycol 3.0 g, propylene glycol 0.6 g, sodium EDTA 0.1 g, guar gum 0.3 g, zinc dioxide 2.0 g, C12-15 benzoate 4.0 g, C12-20 alkyl glucoside 3.0 g, C14-22 alcohol 0.5 g, cetearyl alcohol 1.2 g, parabens 0.2 g, sodium stearate 0.3 g, polydimethylsiloxane alcohol 0.5 g, polysorbate 0.2 g, deionized water 60 g.

[0107] 3. Preparation process

[0108] Weigh out the prescribed amount of Dendrobium officinale flower extract PGG100 and dissolve it completely in purified water. Take glycerin, butylene glycol, propylene glycol, sodium EDTA, guar gum, zinc dioxide, sodium stearate, C12-15 benzoate, C12-20 alkyl glucoside, C14-22 alcohol, and cetearyl alcohol, and mix them with purified water. Take parabens, polydimethylsiloxane alcohol, and polysorbate, and mix them with purified water. Combine the prepared solutions, stir thoroughly, and bottle to obtain the final product.

[0109] Example 6:

[0110] Add the excipients to the Dendrobium officinale flower extract PGG100 at a weight ratio of 1:1, then granulate and compress the mixture into tablets.

[0111] Example 7:

[0112] Add the excipients to the Dendrobium officinale flower extract PGG100 at a weight ratio of 1:2, then granulate and compress the mixture into tablets.

[0113] Example 8:

[0114] Tablets: Dendrobium officinale flower extract PGG100 10mg, lactose 180mg, starch 55mg, magnesium stearate 5mg; Preparation method: Mix Dendrobium officinale flower extract PGG100, lactose and starch, moisten evenly with water, sieve and dry the moistened mixture, sieve again, add magnesium stearate, and then compress the mixture into tablets, each weighing 250 mg, with a compound content of 10 mg.

[0115] Example 9:

[0116] Take Dendrobium officinale flower extract PGG100 and prepare it into capsules according to conventional capsule preparation methods.

[0117] Example 10:

[0118] Capsules: Dendrobium officinale flower extract PGG100 10 mg, lactose 187 mg, magnesium stearate 3 mg;

[0119] Preparation method: Mix Dendrobium officinale flower extract PGG100 with adjuvants, sieve, mix evenly, and fill the resulting mixture into hard gelatin capsules, each capsule weighing 200 mg and containing 10 mg of active ingredient.

[0120] Example 11:

[0121] For external application ointment: Melt the base ingredients (such as beeswax and coconut oil) by heating in a water bath, add Dendrobium officinale flower extract PGG100 and stir well. After cooling, put it into a sterilized sealed container and refrigerate.

Claims

1. Dendrobium officinale flower extract PGG100, characterized in that: It is prepared by the following method: Dried Dendrobium officinale flowers were extracted three times with 90% ethanol at 70 °C for 3 h each time. The extracts were combined and concentrated using a rotary evaporator at 60 °C to obtain a crude extract. Distilled water was added to the crude extract to form a suspension, and an equal volume of petroleum ether was added for extraction five times. The organic phase was concentrated under reduced pressure using a rotary evaporator at 60 °C to obtain the petroleum ether extract. After petroleum ether extraction, the remaining aqueous phase was extracted five times with an equal volume of ethyl acetate. The organic phase was concentrated under reduced pressure using a rotary evaporator at 60 °C to obtain the ethyl acetate extract. After ethyl acetate extraction, an equal volume of n-butanol was extracted five times. The organic phase was concentrated under reduced pressure using a rotary evaporator at 60 °C to obtain the n-butanol extract PGG100.

2. A method for preparing Dendrobium officinale flower extract PGG100, characterized in that, The method includes the following steps: Dried Dendrobium officinale flowers are extracted three times with 90% ethanol at 70 °C for 3 hours each time. The extracts are combined and concentrated using a rotary evaporator at 60 °C to obtain a crude extract. Distilled water is added to the crude extract to form a suspension, and an equal volume of petroleum ether is added for extraction five times. The organic phase is concentrated under reduced pressure using a rotary evaporator at 60 °C to obtain the petroleum ether extract. After petroleum ether extraction, the remaining aqueous phase is extracted five times with an equal volume of ethyl acetate. The organic phase is concentrated under reduced pressure using a rotary evaporator at 60 °C to obtain the ethyl acetate extract. After ethyl acetate extraction, an equal volume of n-butanol is extracted five times. The organic phase is concentrated under reduced pressure using a rotary evaporator at 60 °C to obtain the n-butanol extract PGG100.

3. The use of the Dendrobium officinale flower extract PGG100 as described in claim 1 in the preparation of a drug for anti-UVA-induced skin aging, repair of skin damage, and reduction of scar formation.

4. A pharmaceutical composition comprising the Dendrobium officinale flower extract PGG100 as described in claim 1 and a pharmaceutically acceptable carrier.

5. The use of the pharmaceutical composition of claim 4 in the preparation of a medicament for anti-UVA-induced skin aging, repair of skin damage, and reduction of scar formation.

6. The use of the Dendrobium officinale flower extract PGG100 as described in claim 1 in the preparation of drugs or cosmetics for wound repair.

7. A cosmetic product, comprising the Dendrobium officinale flower extract PGG100 as described in claim 1 as an active ingredient, plus conventional cosmetic excipients.

8. The application of the Dendrobium officinale flower extract PGG100 as described in claim 1 in the preparation of cosmetics for anti-UVA-induced skin aging, repair of skin damage, and reduction of scar formation.

9. The method for preparing the cosmetic according to claim 7, characterized in that, The method includes the following steps: first, obtaining Dendrobium officinale flower extract PGG100 by the preparation method described in claim 2, and then adding commonly used cosmetic excipients.

10. The use of the Dendrobium officinale flower extract PGG100 according to claim 1 in the preparation of drugs or cosmetics that promote elastin gene expression and synthesis.

Images